

PTO/SB/08A (07-05)
Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/589,688
Filing Date	August 17, 2006
First Named Inventor	Mark Greene
Art Unit	To be Determined
Examiner Name	To be Determined
Attorney Docket Number	UPN0017-100 (P3086)

Sheet	1	of	5
-------	---	----	---

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. *	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear
		Number - Kind Code* (if known)	MM-DD-YYYY		
AA	US-5,328,985		07-12-1994	Takeshi Sano et al.	
AB	US-6,391,590		05-21-2002	Takeshi Sano et al.	
AC	US-6,413,934		07-02-2002	Patrick S. Stayton et al.	
AD	US-6,451,995		09-17-2002	Nai-Kong V. Cheung et al.	
AE	US-6,497,881		12-24-2002	Daniel Menuelo et al.	
AF	US-7,144,991		12-05-2006	Stephen Goshorn et al.	
AG	US-5,334,702		08-02-1994	Mark I. Greene et al.	
AH	US-5,663,144		09-02-1997	Mark I. Greene et al.	
AI	US-5,919,764		07-06-1999	Mark I. Greene et al.	
AJ	US-6,022,523		02-08-2000	William F. Degrado et al.	
AK	US-6,100,377		08-08-2000	Mark I. Greene et al.	
AL	US-7,045,286		05-16-2006	Mark I. Greene et al.	
AM	US-6,743,592		06-01-2004	Mark I. Greene et al.	
AN	US 2002-0094534		10-15-2001	Mark I. Greene et al.	
AO	US-5,922,553		07-13-1999	James Eberwine et al.	
AP	US-5,665,539		09-09-1997	Takeshi Sano et al.	

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner
Signature

/Samuel Liu/

Date Considered

06/21/2010

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of text form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard 3.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.58. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.L/



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 5

Complete if Known

Application Number	10/589,888
Filing Date	August 17, 2006
First Named Inventor	Mark Greene
Art Unit	To be Determined
Examiner Name	To be Determined
Attorney Docket Number	UPN0017-100 (P3086)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AQ	Argarana, et al., "Molecular cloning and nucleotide sequence of the streptavidin gene," <i>Nucleic Acids Res.</i> (1986), 14 (4): 1871-1882.	
	AR	Chirinos-Rojas, C.L. et al., "A peptidomimetic antagonist of TNF-alpha-mediated cytotoxicity identified from a phage-displayed random peptide library," <i>J Immunol.</i> (1998), 161(10):5621-6	
	AS	Dubel, S. et al., "Bifunctional and multimeric complexes of streptavidin fused to single chain antibodies (scFv)," <i>J Immunol Methods</i> (1995), 178(2):201-5.	
	AT	Felix, A.M., "Applications of BOP reagent in solid phase synthesis", <i>Int. J. Pep. Prot. Res.</i> 1988 31:231-238.	
	AU	Giralt, E. and Andreu eds, <i>In Peptides</i> , ESCOM, Leiden, The Netherlands 1991,131-133.	
	AV	Hruby, "Conformational restrictions of biologically active peptides via amino acid side chain groups," <i>Life Sci.</i> (1982) 31: 189-199.	
	AW	Karp, et al., "Identification of biotinylated molecules using a baculovirus-expressed luciferase-streptavidin fusion protein," <i>Biotechniques</i> (1996), 20 (3): 452-456, 458-459.	
	AX	Kipriyanov, et al., "Affinity enhancement of a recombinant antibody: formation of complexes with multiple valency by a single-chain Fv fragment-core streptavidin fusion," <i>Protein Eng.</i> (1996), 9 (2): 203-211.	
	AY	Kipriyanov, et al., "Single-chain antibody streptavidin fusions: tetrameric bifunctional scFv-complexes with biotin binding activity and enhanced affinity to antigen," <i>Hum. Antibodies Hybridomas</i> (1995), 6 (3): 93-101.	
	AZ	Kishore, et al., "A recombinant homotrimer, composed of the alpha helical neck region of human surfactant protein D and C1q B chain globular domain, is an inhibitor of the classical complement pathway," <i>J. Immunol</i> (2001) 166: 559-565.	
Examiner Signature	/Samuel Liu/		Date Considered 06/21/2010

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant is to place a check mark here if English language translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08B(07-05)

Approved for use through 07/31/2005. OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3 of 5

Complete if Known

Application Number	10/589,688
Filing Date	August 17, 2006
First Named Inventor	Mark Greene
Art Unit	To be Determined
Examiner Name	To be Determined
Attorney Docket Number	UPN0017-100 (P3086)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	BA	Koo, et al., "Development of a streptavidin-conjugated single-chain antibody that binds <i>Bacillus cereus</i> spores," <i>Applied Environ. Microbiol.</i> (1998), 64 (7): 2497-2502.	
	BB	Le, et al., "A streptavidin-cellulose-binding domain fusion protein that binds biotinylated proteins to cellulose," <i>Enzyme Microb. Technol.</i> 16 (6): 496-500, 1994	
	BC	Lee, W. et al., "Solution structure of the tetrameric minimum transforming domain of p53," <i>Nature Struct. Biol.</i> (1994), 1: 877-890.	
	BD	Murali et al., "Structure-based design of immunologically active therapeutic peptides," <i>Immunol. Res.</i> (1998) 17: 163-169.	
	BE	Ohno and Meruelo, "Multi-drug delivery system using streptavidin-transforming growth factor- α chimeric protein," <i>DNA Cell Biol.</i> (1996), 15 (5): 401-406.	
	BF	Ohno, et al., "Cell-specific, multidrug delivery system using streptavidin-protein A fusion protein," <i>Biochem. Mol. Med.</i> (1996) 58 (2): 227-233.	
	BG	Pearce, et al. "Linear gene fusions of antibody fragments with streptavidin can be linked to biotin labelled secondary molecules to form bispecific reagents," <i>Biochem. Mol. Biol. Int.</i> (1997) 42 (6): 1179-1188.	
	BH	Ploux, O. et al., "Cyclization of peptides on a solid support. Application to cyclic analogs of substance P," <i>Int. J. Pep. Prot. Res.</i> (1987), 29: 162-169.	
	BI	Porstmann, T. et al., "Enzyme immunoassay techniques. An overview," <i>J Immunol Methods.</i> (1992), 150(1-2):5-21.	
	BJ	Porstmann, B. et al., "Which of the commonly used marker enzymes gives the best results in colorimetric and fluorimetric enzyme immunoassays: horseradish peroxidase, alkaline phosphatase or beta-galactosidase?" <i>J Immunol Methods</i> (1985), 79(1):27-37.	
	BK	Prasad et al., "Contrasting solution conformations of peptides containing alpha, alpha-dialkylated residues with linear and cyclic side chains," <i>Biopolymers</i> (1995) 35: 11-20.	

Examiner
Signature

/Samuel Liu/

Date
Considered

06/21/2010

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 38 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.L./



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Patent Application Form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 4 of 5

Complete if Known

Application Number	10/589,688
Filing Date	August 17, 2006
First Named Inventor	Mark Greene
Art Unit	To be Determined
Examiner Name	To be Determined
Attorney Docket Number	UPN0017-100 (P3086)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	BL	Rogers et al., "Characterization of disulfide crosslink formation of human vimentin at the dimer, tetramer, and intermediate filament levels," <i>J Struct Biol.</i> (1996) Jul-Aug; 117 (1): 55-69	
	BM	Roland J. et al., "The synthetic CD4 exocytic CDR3.AME(82-89) inhibits NF-kappaB nuclear translocation, HIV-1 promoter activation, and viral gene expression," <i>DNA Cell Biol.</i> (1999), Nov:18(11):819-28.	
	BN	Romaní, S. et al., "Synthesis of the trypsin fragment 10-25/75-88 of mouse nerve growth factor. II. The unsymmetrical double chain cystine peptide," <i>Int. J. Pep. Prot. Res.</i> (1987), 29: 107-117.	
	BO	Sano and Cantor, "Expression of a cloned streptavidin gene in <i>Escherichia coli</i> ," <i>Proc. Natl. Acad. Sci. USA</i> (1990), 87 (1): 142-146.	
	BP	Sano and Cantor, "A streptavidin-protein A chimera that allows one-step production of a variety of specific antibody conjugates," <i>Biotechnology</i> (1991), 1378-1381.	
	BQ	Sano and Cantor, "Expression vectors for streptavidin-containing chimeric proteins," <i>Biochem. Biophys. Res. Commun.</i> (1991), 176 (2): 571-577.	
	BR	Sano et al., "A streptavidin-metallothionein chimera that allows specific labeling of biological materials with many different heavy metal ions," <i>Proc. Natl. Acad. Sci. USA</i> (1998), 89 (5): 1534-1538.	
	BS	Saragovi et al., "Design and synthesis of a mimetic from an antibody complementarity-determining region," <i>Science</i> (1991), 253: 792-795.	
	BT	Schiller et al., "Synthesis of side-chain to side-chain cyclized peptide analogs on solid supports," <i>Int. J. Pep. Prot. Res.</i> (1985), 25: 171-177.	
	BU	Schweitzer et al., "Inaugural article: immunoassays with rolling circle DNA amplification: a versatile platform for ultrasensitive antigen detection," <i>Proc Natl Acad Sci U S A.</i> (2000), 97(18):10113-9.	
	BV	Sheppard, R. C., "Acid-labile resin linkage agents for use in solid phase peptide synthesis," <i>Int. J. Peptide Res.</i> (1982), 20: 451-454.	
Examiner Signature	/Samuel Liu/		Date Considered 06/21/2010

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.L./



PTO/SB/08B(07-05)

Approved for use through 07/31/2008. OMB 0551-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 5 of 5

Complete if Known

Application Number	10/589,588
Filing Date	August 17, 2006
First Named Inventor	Mark Greene
An Unit	To be Determined
Examiner Name	To be Determined
Attorney Docket Number	UPN0017-100 (P3086)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	BW	Srinivasan, M. et al., "Immunomodulatory peptides from IgSF proteins: a review," <i>Curr Protein Pept Sci.</i> (2005), 6(2):185-96.	
	BX	Tannous et al., "T7 RNA polymerase as a self-replicating label for antigen quantification," <i>Nucleic Acids Res</i> (2002), 30(24):e140.	
	BY	Walsh and Swaisgood, "An <i>Escherichia coli</i> plasmid vector system for production of streptavidin fusion proteins: Expression and bioselective adsorption of streptavidin- β -galactosidase," <i>Biotech. Bioeng.</i> (1994) 44: 1348-1354.	
	BZ	Williams et al., "Development of biologically active peptides based on antibody structure," <i>Proc. Natl Acad. Sci. USA</i> (1989), 66: 5537-5541.	
	CA	Zhang X. et al., "Synthetic CD4 exocyclics inhibit binding of human immunodeficiency virus type 1 envelope to CD4 and virus replication in T lymphocytes," <i>Nat Biotechnol.</i> (1997), 15(2):150-4.	
	CB	Zhang et al., "Crystal structure of recombinant human platelet factor 4," <i>Biochem</i> (1994), V33: 8361-8366.	

Examiner Signature	/Samuel Liu/	Date Considered	06/21/2010
--------------------	--------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language. Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.L./